Abstract
The release of hormones is subject to a complex and finely tuned regulation system. The biosynthesis plays a key role by specifically converting the prohormone precursor into its biological active product(s). A family of mammalian proteases could be identified to be responsible for the endoproteolytic processing. These subtilisin / kexin-like prohormone convertases (PC) recognize their substrates at single or pairs of basic residues with a high substrate specificity. The so far known seven members include PC1 / 3, PC2, furin / PACE, PACE4, PC4, PC5 / 6 and PC7 / SPC7 / LPC / PC8. PC1 / 3 and PC2 are the most important enzymes for the processing of prohormones, whereas furin is the only one that causes lethality in knock-out models. Tissuespecific co-localization of the prohormone and the PC as well as distinct characteristics of both, like the secondary structures, determine the possible conversion processes. Identification of such determinants implies a great potential for the development of novel drug targets. To obtain sufficient amounts for the in vitro characterization of prohormones, chemical and recombinant synthesis methods have been developed. Application of expressed protein ligation lead to the semisynthesis of the first chemically modified analogs of a full-length proneurohormone (pro-neuropeptide Y). Structural analyses mainly on peptides of the prooxytocin / neurophysin system and on prosomatostatin highlighted the importance of flexible turn or loop structures adjacent to the cleavage site for the specific substrate-enzyme active site interaction. Prohormones and their processing show multiple functions. Therapeutic application including PC inhibitors is very promising for the treatment of disorders like cancer.
Keywords: hormone biosynthesis, prohormone convertase, substrate specificity, recombinant expression, expressed protein ligation, chemical modification, secondary structure, inhibitor
Current Medicinal Chemistry
Title: Biosynthesis of Peptide Hormones Derived from Precursor Sequences
Volume: 11 Issue: 20
Author(s): R. von Eggelkraut-Gottanka and A. G. Beck-Sickinger
Affiliation:
Keywords: hormone biosynthesis, prohormone convertase, substrate specificity, recombinant expression, expressed protein ligation, chemical modification, secondary structure, inhibitor
Abstract: The release of hormones is subject to a complex and finely tuned regulation system. The biosynthesis plays a key role by specifically converting the prohormone precursor into its biological active product(s). A family of mammalian proteases could be identified to be responsible for the endoproteolytic processing. These subtilisin / kexin-like prohormone convertases (PC) recognize their substrates at single or pairs of basic residues with a high substrate specificity. The so far known seven members include PC1 / 3, PC2, furin / PACE, PACE4, PC4, PC5 / 6 and PC7 / SPC7 / LPC / PC8. PC1 / 3 and PC2 are the most important enzymes for the processing of prohormones, whereas furin is the only one that causes lethality in knock-out models. Tissuespecific co-localization of the prohormone and the PC as well as distinct characteristics of both, like the secondary structures, determine the possible conversion processes. Identification of such determinants implies a great potential for the development of novel drug targets. To obtain sufficient amounts for the in vitro characterization of prohormones, chemical and recombinant synthesis methods have been developed. Application of expressed protein ligation lead to the semisynthesis of the first chemically modified analogs of a full-length proneurohormone (pro-neuropeptide Y). Structural analyses mainly on peptides of the prooxytocin / neurophysin system and on prosomatostatin highlighted the importance of flexible turn or loop structures adjacent to the cleavage site for the specific substrate-enzyme active site interaction. Prohormones and their processing show multiple functions. Therapeutic application including PC inhibitors is very promising for the treatment of disorders like cancer.
Export Options
About this article
Cite this article as:
Eggelkraut-Gottanka von R. and Beck-Sickinger G. A., Biosynthesis of Peptide Hormones Derived from Precursor Sequences, Current Medicinal Chemistry 2004; 11 (20) . https://dx.doi.org/10.2174/0929867043364405
DOI https://dx.doi.org/10.2174/0929867043364405 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Battle of the Sexes for Stroke Therapy: Female- Versus Male-Derived Stem Cells
CNS & Neurological Disorders - Drug Targets RAGE: A Single Receptor for Several Ligands and Different Cellular Responses: The Case of Certain S100 Proteins
Current Molecular Medicine Immunotherapy in Breast Cancer- Paving New Roads?
Current Molecular Pharmacology Gene Electrotransfer to Skin; Review of Existing Literature and Clinical Perspectives
Current Gene Therapy Vitamin D - Pivotal Nutraceutical in the Regulation of Cancer Metastasis and Angiogenesis
Current Medicinal Chemistry Novel Agents in the Management of Lung Cancer
Current Medicinal Chemistry Antioxidant Enzyme Mimics with Synergism
Mini-Reviews in Medicinal Chemistry “Bedside-to-Bench” Behavioral Outcomes in Animal Models of Pain: Beyond the Evaluation of Reflexes
Current Neuropharmacology Kolaviron, A Biflavonoid Compound: Its Pharmacological Activity and Therapeutic Efficacy
Current Bioactive Compounds The Heat Stress Response and Diabetes: More Room for Mitochondrial Implication
Current Pharmaceutical Design Leptin as Clinical Target
Recent Patents on Inflammation & Allergy Drug Discovery Frailty of Older Age: The Role of the Endocrine - Immune Interaction
Current Pharmaceutical Design Adipose Tissue Macrophages, Low Grade Inflammation and Insulin Resistance in Human Obesity
Current Pharmaceutical Design Breast Cancer: Current Developments in Molecular Approaches to Diagnosis and Treatment
Recent Patents on Anti-Cancer Drug Discovery GLP-1 Receptor Agonists and Type 1 Diabetes - Where Do We Stand?
Current Pharmaceutical Design Assessing the Neuronal Serotonergic Target-based Antidepressant Stratagem: Impact of In Vivo Interaction Studies and Knockout Models
Current Neuropharmacology Pharmacogenetics of Target Genes Across Doxorubicin Disposition Pathway: A Review
Current Drug Metabolism Cyclodextrin-Based Polysaccharidic Polymers: An Approach for the Drug Delivery
Current Topics in Medicinal Chemistry Therapeutic Targets for Management of Periodontitis and Diabetes
Current Pharmaceutical Design Endocrine Therapy of Breast Cancer
Current Medicinal Chemistry